IGF-1 and Growth Response to Adult Height in a Randomized GH Treatment Trial in Short Non-GH-Deficient Children

被引:31
|
作者
Kristrom, Berit [1 ,3 ]
Lundberg, Elena [1 ]
Jonsson, Bjorn [2 ]
Albertsson-Wikland, Kerstin [3 ]
机构
[1] Umea Univ, Dept Clin Sci, SE-90185 Umea, Sweden
[2] Uppsala Univ, Dept Womens & Childrens Hlth, SE-75185 Uppsala, Sweden
[3] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Goteborg Pediat Growth Res Ctr,Dept Pediat, SE-41685 Gothenburg, Sweden
来源
基金
瑞典研究理事会;
关键词
IDIOPATHIC SHORT STATURE; FOR-GESTATIONAL-AGE; LONG-TERM MORTALITY; HORMONE TREATMENT; BINDING PROTEIN-3; FACTOR-I; PREPUBERTAL CHILDREN; FINAL HEIGHT; SECRETION CAPACITIES; PREDICTION MODELS;
D O I
10.1210/jc.2014-1101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: GH treatment significantly increased adult height (AH) in a dose-dependent manner in short non-GH-deficient children in a randomized, controlled, clinical trial; the mean gain in height SD score (height(SDS)) was 1.3 (range 0-3), compared with 0.2 in the untreated group. Objective: The objective of the study was to analyze the relationship between IGF-1(SDS), IGF binding protein-3 SDS (IGFBP3(SDS)), and their ratio(SDS) with a gain in the height(SDS) until AH in non-GH-deficient short children. Design and Setting: This was a randomized, controlled, multicenter clinical trial. Intervention: The intervention included GH treatment: 33 or 67 mu g/kg.d plus untreated controls. Subjects: One hundred fifty-one non-GH-deficient short children were included in the intent-to-treat (ITT) population and 108 in the per-protocol (PP) population; 112 children in the ITT and 68 children in the PP populations had idiopathic short stature (ISS). Main Outcome Measures: Increments from baseline to on-treatment study mean IGF-1(SDS) (Delta IGF-1(SDS)), IGFBP3(SDS), and IGF-1 to IGFBP3 ratio(SDS) were assessed in relationship to the gain in height(SDS). Results: Sixty-two percent of the variance in the gain in height(SDS) in children on GH treatment could be explained by four variables: Delta IGF-1(SDS) (explaining 28%), bone age delay, birth length (the taller the better), and GH dose (the higher the better). The lower IGF-1(SDS) was at baseline, the higher was its increment during treatment. For both the All(PP)- and the ISSPP-treated groups, the attained IGF-1(SDS) study level did not correlate with height gain. Conclusion: In short non-GH-deficient children, the GH dose-related increment in IGF-1(SDS) from baseline to mean study level was the most important explanatory variable for long-term growth response from the peripubertal period until AH, when IGF-1(SDS), IGFBP3(SDS), and their ratio(SDS) were compared concurrently.
引用
收藏
页码:2917 / 2924
页数:8
相关论文
共 50 条
  • [21] Growth hormone (GH) secretion, IGF-1 and IGFBP-3 can predict response to GH therapy
    Purushothaman, Radhika
    Bhangoo, Amrit
    Fernandes, Priyanka
    Bhandari, Sonal
    Ten, Svetlana
    HORMONE RESEARCH, 2009, 72 : 201 - 201
  • [22] Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: Results of a randomized, double-blind, dose-response GH trial
    van Pareren, Y
    Mulder, P
    Houdijk, M
    Jansen, M
    Reeser, M
    Hokken-Koelega, A
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (08): : 3584 - 3590
  • [23] Use of growth hormone (GH) in non-GH deficient short stature
    Menon, P. S. N.
    INDIAN JOURNAL OF PEDIATRICS, 2008, 75 (01): : S14 - S19
  • [24] A PARTIAL TRANSIENT EFFECT OF SHORT-TERM GROWTH-HORMONE (GH) TREATMENT IN SHORT NON-GH DEFICIENT PREPUBERTAL CHILDREN
    LOW, LCK
    KWAN, E
    KARLBERG, J
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 1995, 8 (03): : 173 - 179
  • [25] Local expression of GH and IGF-1 in the hippocampus of GH-deficient long-lived mice
    Sun, LY
    Al-Regaiey, K
    Masternak, MM
    Wang, H
    Bartke, A
    NEUROBIOLOGY OF AGING, 2005, 26 (06) : 929 - 937
  • [26] Suppression and recovery of GH secretion after GH injection in non-GH deficient short children
    Rose, SR
    Baron, J
    Bernstein, D
    Yanovski, J
    Troendle, JF
    Leschek, E
    Chipman, J
    Cutler, GB
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2000, 13 (03): : 281 - 288
  • [27] Adult Height in Short Children Born SGA Treated with Growth Hormone and Gonadotropin Releasing Hormone Analog: Results of a Randomized, Dose-Response GH Trial
    Lem, Annemieke J.
    van der Kaay, Danielle C. M.
    de Ridder, Maria A. J.
    Bakker-van Waarde, Willie M.
    van der Hulst, Flip J. P. C. M.
    Mulder, Jaap C.
    Noordam, Cees
    Odink, Roel J.
    Oostdijk, Wilma
    Schroor, Eelco J.
    Sulkers, Eric J.
    Westerlaken, Ciska
    Hokken-Koelega, Anita C. S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (11): : 4096 - 4105
  • [28] Predictive factors to response to GH treatment and final height in children with GH deficiency
    Gaudino, Rossella
    Dal Corso, Sara
    Cavarzere, Paolo
    Banzato, Claudia
    Franceschi, Roberto
    Antoniazzi, Franco
    Tato, Luciano
    HORMONE RESEARCH, 2009, 72 : 250 - 250
  • [29] GROWTH-HORMONE THERAPY IN NON GH-DEFICIENT SHORT CHILDREN
    SPADONI, GL
    VACCARO, F
    BERNARDINI, S
    CIANFARANI, S
    BITTI, MLM
    SPAGNOLI, A
    COSTA, F
    BOSCHERINI, B
    PEDIATRIC RESEARCH, 1989, 26 (05) : 527 - 527
  • [30] High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pre-treatment GH secretion and associated with a reversible decrease in insulin sensitivity
    De Zegher, F
    Ong, K
    Van Helvoirt, M
    Mohn, A
    Woods, K
    Dunger, D
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01): : 148 - 151